Overdose and anaphylaxis are two serious medical emergencies that require immediate intervention and can be fatal if not treated in time. Supplying every AED first-aid box with epinephrine ...
RICHMOND, Va.--(BUSINESS WIRE)--Please replace the release dated March 2, 2022, with the following corrected version due to multiple revisions. The updated release ...
Severe opioid-induced respiratory depression (OIRD) can be treated with intranasal (IN) or intramuscular (IM) naloxone. It is relevant to compare their efficacy and determine the optimal strategy to ...
SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that an article entitled “Comparative Pharmacokinetic Analysis of Community ...
Strategies to expand access to naloxone (Narcan) for the prevention of opioid overdoses were explored during a webinar hosted by the Reagan-Udall Foundation for the FDA on Tuesday. Over 100,000 people ...
SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the publication of an article entitled “An open-label, randomized, single-dose, ...
The MarketWatch News Department was not involved in the creation of this content. Richmond, Virginia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kaléo, a global leader in drug-delivery device technology and ...
Clinicians have not widely adopted the co-prescription of naloxone with opioids or the distribution of naloxone kits and education to laypersons in the past for fear of legal ramifications. As of July ...
The US Food and Drug Administration (FDA) has approved a high-dose naloxone injection product for the emergency treatment of opioid overdose. ZIMHI from Adamis Pharmaceuticals is administered using a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results